TP53 mutations are generally associated with a poorer prognosis in various cancers. They are often linked with more aggressive disease, higher rates of metastasis, and resistance to conventional therapies. Histologically, this manifests as tumors with high-grade features and extensive invasion into surrounding tissues.
